Validation of a multi-gene qPCR-based pharmacogenomics panel across major ethnic groups in Singapore and Indonesia

Running Title

Multi-gene qPCR-based PGx panel for Asians

Authors

Anar Sanjaykumar KOTHARY^{1,2,*}, Caroline MAHENDRA^{1,*}, Mingchen TAN¹, Eunice Jia Min TAN³, Jacelyn PHUA Hong Yi¹, GABRIELLA¹, TAN Xin Hui Jocelyn¹, Jessline Stephanie HARUMAN¹, Zhihao TAN^{1,2}, Chun Kiat LEE³, Alexander LEZHAVA², Benedict YAN^{3,4}, Astrid IRWANTO^{1,5,#}

Affiliations

¹Nalagenetics Pte Ltd, Singapore, Singapore

²Center for Genome Diagnostics, Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore

³Department of Laboratory Medicine, National University Health System, Singapore

⁴Stronghold Diagnostics Lab, Agency for Science, Technology and Research, Singapore

⁵Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore

Acknowledgements

We would like to thank Mr. Xie Zhicheng and Mr. Heng Khai Koon at the Genome Institute of Singapore for their assistance with performing the Agena VeriDose® Core and *CYP2D6* CNV Panel studies. We also thank PT Nalagenetik Riset Indonesia for their assistance in study recruitment and experimentation performed in Indonesia, and Genome Institute of Singapore for providing facility to perform all experimentations done in Singapore.

^{*}equal contribution

^{*}corresponding author: astrid@nalagenetics.com

23

4

5

6

7 8

9

10

1112

13

14

15

16 17

18

19

20

21

22

23

2425

26

27

28

2930

31

3233

34

Abstract Background – With up to 70% of adverse drug reactions (ADRs) having high genetic associations, the clinical utility of pharmacogenomics (PGx) has been gaining traction. Nala PGx CoreTM is a multi-gene qPCR-based panel that comprises 18 variants and 2 CYP2D6 Copy Number markers across 4 pharmacogenes - CYP2C9, CYP2C19, CYP2D6 and SLCO1B1. Objectives – In this study, we validated the performance of Nala PGx CoreTM against benchmark methods, on the Singaporean and Indonesian populations. Additionally, we examined the allele and diplotype frequencies across 5 major ethnic groups present in these populations namely, Indonesians, Chinese, Malays, Indians and Caucasians. Methods – Human gDNA samples, extracted from the buccal swabs of 246 participants, were tested on Nala PGx CoreTM and two chosen benchmarks, Agena VeriDose® Core and CYP2D6 Copy Number Variation (CNV) Panel, and TaqMan® DME Genotyping Assays. Performance was evaluated based on assay robustness, precision and accuracy at the genotype- and diplotype-level. Results - Nala PGx CoreTM demonstrated high genotype- and diplotype-level call rates of >97% and >95% respectively in CYP2D6, and 100% for CYP2C9, CYP2C19 and SLCO1B1. A precision rate of 100% was observed on both intra- and inter-precision studies. Variant-level concordance to the benchmark methods was ≥96.9% across all assays, which consequently resulted in a diplotype-level concordance of >94.7% across CYP2C9, CYP2C19 and CYP2D6. Overall, the allele frequencies of CYP2D6*10 and CYP2D6*36 were higher in our cohort as compared to previous records. Notably, CYP2D6 copy number variation (CNV) analysis demonstrated a CYP2D6 *10/*36 frequency of 26.5% amongst the Indonesian cohort. Conclusion -Nala PGx CoreTM produced robust and accurate genotyping when compared to other established benchmarks. Furthermore, the panel successfully characterized alleles of clinical relevance in the Singaporean and Indonesian populations such as CYP2D6*10 and CYP2D6*36, suggesting its potential for adoption in clinical workflows regionally. Keywords: Pharmacogenomics; CYP2C9; CYP2C19; CYP2D6; SLCO1B1; qPCR; adverse drug reactions; Singapore; Indonesia. Abstract count: 290 words, 1764 characters Main text count: 4337 words

Introduction

- Pharmacogenomics (PGx) is a branch of medicine concerned with determining the response of an individual to therapeutic drugs using genetic and/or genomic information¹. With up to 70% of adverse drug reactions (ADRs) having high genetic associations², and the sunk cost of trial-and-error prescriptions amounting to USD 30 billion³.
- 39 the clinical utility⁴ of PGx appears to be gaining prominence.
 - Applications of PGx include the genotyping of Cytochrome P450 (P450) enzymes which are significantly involved in drug metabolism and chemical toxicity⁵. *CYP2C9*, *CYP2C19* and *CYP2D6* display common polymorphisms that produce altered enzyme activity, often resulting in deviant drug metabolism that leads to side effects from drugs metabolized by them⁵.
 - Alterations in *CYP2C9* can disrupt the metabolism of warfarin, while *CYP2C19* is associated with the metabolism of a number of drugs including clopidogrel, omeprazole and phenytoin^{6,7}. The highly polymorphic *CYP2D6* has more than 100 variants and is responsible for the metabolism of approximately 25% of all clinically used drugs, including codeine, fluoxetine and amitriptyline⁷. For this reason, pharmaceuticals are particularly cautious in the development of drugs that are known to interact with these three P450s⁵. Additionally, pharmacogenes, such as *SLCO1B1*, are responsible for encoding transporters of simvastatin and other statins into tissues also affect their response upon intake in individuals. Variants of this gene are associated with increased risk of muscle pain (myalgia) and damage, including myopathy and in severe cases rhabdomyolysis⁸. Previous studies suggest the role of specific *CYP2C19* and *SLCO1B1* variants in the bioactivation of drugs such as clopidogrel and atorvastatin in the Singaporean population^{9,10}. The *CYP2C19* variant, rs4986893, which is implicated in reduced clopidogrel metabolism, has been observed to be 50 times more prevalent in the Singaporean Chinese population than in Europeans¹⁰. The *SLCO1B1* variant, rs4149056, which is implicated in statin metabolism, has been observed to occur less frequently in the Singaporean population⁹. Taken together, these cases highlight the need to harness PGx testing to account for population differences in the personalization of prescriptions¹¹.
 - Current methods on PGx testing for the identification of genetic polymorphisms revolve around variant genotyping that utilize technologies ranging from Next Generation Sequencing (NGS), Microarray, Mass Spectrometry to Quantitative PCR (qPCR)^{1,6,12,13}. Main considerations in the adoption of a platform include its robustness, effectiveness and cost-saving, especially in localities with limited resources. qPCR-based assays satisfy these criteria and are a preferred platform for clinical laboratories^{14–19}. However, some of the available commercial kits are limited in their ability to test the 4 genes of interest mentioned above in a single panel^{20–25}. Nala PGx CoreTM is a qPCR-based multi-gene panel consisting of 20 pharmacogenomic variants that are associated with altered *CYP2C9*, *CYP2C19*, *CYP2D6* and *SLCO1B1* activity in Asian geographies. Our study aims to evaluate the performance of Nala PGx CoreTM in effectively identifying genetic variations that may contribute to PGx-related clinical outcomes in Singapore and Indonesia, with a secondary objective of highlighting the allele and diplotype frequencies in the geographies examined.

Methods and Materials

Ethics Approval

72

73

77

84

92

99

- 74 Institutional Review Board (IRB) approval was granted by the Parkway Independent Ethics Committee (Singapore)
- 75 under IRB Reference Number PIEC/2019/021 and Siloam Hospitals Ethics Review Committee (Jakarta, Indonesia)
- under IRB Reference Number 001/EA/KEPKK/RSMRCCC/V/2019.

Study Recruitment

- Patients were recruited on behalf of Nalagenetics Pte. Ltd. with written informed consent forms from recruitment
- 79 sites in Singapore and Indonesia. A total of 251 samples were evaluated from 5 major ethnic groups to ensure the
- 80 representation of the major ethnic groups residing in both countries Chinese, Malays, Indians, Caucasians and
- 81 Indonesians. Participants identifying as one or more of the following ethnicities were categorized as Indonesians:
- 82 Ambon, Batak, Betawi, Jawa, Lampung, Manado, Minangkabau, Nusa Tenggara Timur, Palembang, Sulawesi,
- 83 Sunda, Timor Leste, Tolaki and Toraja.
- 85 Buccal samples were collected using OraCollect (Cat No. DNA OCR-100 from DNA Genotek) and genomic DNA
- 86 (gDNA) extracted using the Monarch Genomic DNA Purification Kit (Cat No. T3010 from NEB). The extraction
- procedure followed manufacturer's instructions with additional dry-spin step at maximum speed for 1 minute after
- 88 the 2nd buffer washing step. The quality and concentration of gDNA extracts were quantified by NanoDrop 2000
- 89 Spectrophotometer (Singapore) and BioDrop-µLITE (Indonesia). Samples that failed to meet the DNA quality
- 90 control criteria (n=5) of A260/280 >1.7 and DNA yield >500ng were excluded from the study. The remaining
- 91 extracted gDNA samples (n=246) were stored at -20□ for downstream application.

Nala PGx CoreTM

- 93 The Nala PGx CoreTM kit from Nalagenetics Pte. Ltd. consists of 20 qPCR-based variant assays across four genes –
- 94 CYP2C9, CYP2C19, CYP2D6 and SLC01B1. Whilst assays for CYP2C9, CYP2C19 and CYP2D6 have been
- 95 designed to enable the detection of specific star alleles, the SLCO1B1 assay has been designed to detect the variant
- 96 rs4149056, which is present in three reduced function haplotypes namely, SLC01B1*5, SLC01B1*15 and
- 97 SLC01B1*17. The SLC01B1 assay is thus, unable to differentiate between each of the three aforementioned
- haplotypes. The variants covered by the kit are outlined in Table 1.
- Assays were set up on a 96-well plate. Human gDNA was added at a concentration of 2 ng/µL as template for the
- 101 qPCR reaction, which was then performed on the Bio-Rad CFX96 IVD TouchTM Real-Time PCR Detection System
- per the product insert. Run analysis was performed using the application CFX Manager 3.1 or CFX Maestro, and
- 103 exported as raw .csv files. Exported files were uploaded into the companion software, Nala Clinical Decision
- 104 SupportTM (Nala CDSTM) for further analysis of variant genotyping, diplotype determination and phenotype

translation. Genotyping using Nala PGx CoreTM was performed at the Molecular Diagnosis Centre, National University Health System, Singapore (NUHS MDC) and PT Nalagenetik Riset Indonesia.

Agena VeriDose® Core and CYP2D6 Copy Number Variation (CNV) Panel

- The VeriDose® Core and *CYP2D6* Copy Number Variation (CNV) Panel from Agena Bioscience® consists of 68 variant assays in 20 genes and 5 *CYP2D6* CNV assays, accompanied by a reporting software that automatically analyzes each variation²⁶. Genotyping using Agena VeriDose Core and *CYP2D6* CNV Panel was performed at the Genome Institute of Singapore. Variants evaluated using this platform are listed in Table 1. The Agena VeriDose® Panel has been utilized by the United States Centers for Disease Control and Prevention (CDC) as part of their Genetic Testing Reference Material (GeT-RM) Coordination Program²⁷.
- TaqMan® Drug Metabolism Enzyme (DME) Genotyping Assay
- TaqMan® DME Genotyping Assays were utilized in the evaluation of CYP2D6 rs769258 (TaqMan Assay ID
- 116 AH21B9N) and CYP2D6 rs267608319 (TaqMan Assay ID C_27102444_F0). Assays were set up on a 384-well
- plate²⁸ with a sample input of human gDNA at 2 ng/µL. The subsequent PCR reaction was performed on the
- Applied Biosystems ViiATM 7 Real-Time PCR System as per the recommended cycling conditions, at the Genome
- 119 Institute of Singapore. Post-PCR plate read was performed using the companion software, TaqMan® GenotyperTM
- 120 Software for single nucleotide polymorphisms (SNP) genotyping. Similar to the Agena VeriDose® Panel,
- TaqMan® DME Genotyping Assays were employed in the characterization of DNA samples as part of the CDC
- GeT-RM program²⁷.
- 124 Robustness

105

106

107

108

109

110

111

112

113

114

123

- Genotype- and diplotype-level call rates were defined as the percentage of samples that returned a genotype at the
- variant-level or were assigned a distinct diplotype for the gene of interest, respectively. Failed tests were defined as
- samples that did not return a genotype and/or diplotype call for the genes evaluated.

Call Rates,
$$\% = \frac{\text{Total Sample Size-Failed Tests}}{\text{Total Sample Size}} \times 100\%$$

Precision

Three samples at 3 DNA concentrations were tested across 3 reagent lots on 2 machines. Each test condition was repeated within the same plate for a triplicate. For variant assays that identified SNPs and indels, intra-precision was performed within the same plate, run as triplicates across 47 tests. Inter-precision was assessed from 120 tests performed across plate runs covering the 4 variables – samples, DNA concentration, reagent lots and machines. Concordance rates across precision studies were calculated as the percentage of tests that returned a genotype call concordant to the expected truth for each variant assay. Discordant genotype was defined as instances when the test returned a genotype call that was different from the expected truth.

$$Concordance \ Rate, \% = \frac{\text{No. Of Tests Performed } - \text{No. Of Tests With Discordant Genotype}}{\text{No. Of Tests Performed}} \times 100\%$$

For *CYP2D6* CNV assays, copy number estimates for Intron 2 and Exon 9 of the three samples were derived based on their cycle threshold (Ct) results across plate runs.

Copy Number =
$$2 \times 2^{-\Delta \Delta Ct}$$

$$\Delta \Delta Ct = \left(Ct_{reference \ gene \ calibrator} - Ct_{CYP2D6 \ calibrator}\right) - \left(Ct_{reference \ gene} - Ct_{CYP2D6 \ sample}\right)$$
141

Testing of the three samples was repeated for a number of plate runs, n (Table 5), and calculated for the average copy number of each sample and their coefficient of variation (CV). The CV for each plate run was calculated by finding the standard deviation (σ_{plate}) between triplicates within the same plate run, and divided by the triplicate mean (μ_{plate}). The average of the individual CVs was reported as the intra-precision CV. For inter-precision CV, standard deviation population ($\sigma_{plate\ means}$) was divided by the mean population, i.e. average of means.

$$\text{Intra- CV,\%} = \frac{\sum_{n} \frac{\sigma_{plate}}{\mu_{plate}}}{n} \times 100\%$$

$$\text{Inter- CV,\%} = \frac{\sigma_{\text{plate means}}}{\sum_{n} \mu_{\text{plate}} / n} \times 100\%$$

148 Accuracy

149 Variant-level Concordance

The accuracy of Nala PGx CoreTM in genotyping at a variant-level was evaluated by comparing calls produced by Nala PGx CoreTM assay against benchmark methods as listed in Table 1. Samples that successfully produced genotype calls for all variants tested on Nala PGx CoreTM and its benchmarks were considered for the evaluation (n = 225 for all variants except CYP2D6 CNV; n = 224 for CYP2D6 CNV). Samples that failed to produce a genotype call on one or more of the platforms were excluded from the concordance calculation (n = 21 for all variants except CYP2D6 CNV; n = 22 for CYP2D6 CNV, Supplementary Table 7). Discordant calls were defined as instances in

156 which Nala PGx Core™ provided a genotype call that was different from that of a call made by the corresponding

benchmark. Percentage concordance to the benchmark was calculated per variant as follows –

$$\label{eq:concordance} \mbox{Concordance To Benchmark Per Variant, \%} = \frac{\mbox{Total Sample Size - Discordant Calls By Nala PGx Core^{TM}}}{\mbox{Total Sample Size}} \times 100\%$$

- 158 Diplotype-level Concordance
- 159 The accuracy of Nala PGx Core™ in assigning a diplotype call for CYP2C9, CYP2C19, and CYP2D6, was
- evaluated by comparing calls against the Agena VeriDose® Core and CYP2D6 CNV Panel. Samples that met the
- following criteria were included in the sample size of each gene:
- 162 1. Successful genotype-level calls on the relevant platforms for all variants covered by the gene of interest
- 2. Successful assignment of a diplotype for the gene of interest on both Nala PGx Core™, and Agena
- VeriDose® Core and *CYP2D6* CNV Panel
- Discordant calls were defined as instances in which Nala PGx CoreTM assigned a diplotype that differed from the
- call made by the Agena VeriDose® Core and CYP2D6 CNV Panel.

$$Concordance, \% = \frac{\text{Total Sample Size - Discordant Calls By Nala PGx Core}^{\text{TM}}}{\text{Total Sample Size}} \times 100\%$$

167 Frequencies By Ethnicity

176

- Ethnicities were obtained based on participant self-identification across both the population cohorts as part of the
- 169 recruitment questionnaire. Participants that did not report an ethnic group in the recruitment form were excluded
- from the frequency analysis. The following were further excluded from the frequency analysis:
- 171 1. Samples in which participants did not report an ethnic group on the recruitment form (n=6)
- 2. Samples with one or more variant level failures across the 4 genes evaluated in Table 1 (n=18)
- 3. Samples with one or more diplotype-level failures ("No Call") across *CYP2C9*, *CYP2C19*, and *CYP2D6* on
- Nala PGx CoreTM and the Agena VeriDose® Core and *CYP2D6* CNV Panel (n=15)
- 4. Samples with discordant diplotype calls for the gene of interest (n=variable, Supplementary Table 7)
- The remaining samples were included in the allele-level frequency analysis of CYP2C9 (n=206), CYP2C19 (n=201),
- 178 CYP2D6 (n=195) and SLCO1B1 (n=203), as well as in the diplotype-level frequency analysis of CYP2C9 (n=206),
- 179 CYP2C19 (n=201) and CYP2D6 (n=195). Allele and diplotype frequency values were derived using the following
- formulae^{29,30}, for both the overall study cohort as well as for each ethnic group.

$$Frequency\ Of\ Allele\ 'X'\ In\ A\ Given\ Population = \frac{Total\ Copies\ Of\ Allele\ 'X'}{Total\ Copies\ Of\ All\ Alleles\ For\ The\ Gene\ Of\ Interest}$$

$$Frequency\ Of\ Diplotype\ 'X'\ In\ A\ Given\ Population = \frac{Total\ Instances\ Of\ Diplotype\ 'X'}{Total\ Number\ Of\ Individuals\ In\ The\ Population}$$

Results

182

183

190

198

Robustness

- We first sought to evaluate the observed genotype- and diplotype-level call rates of the platforms evaluated in this study. 246 samples underwent variant genotyping and diplotype determination, across the four genes evaluated on
- the genotyping platforms (Tables 2, 3). The genotype-level call rates for Nala PGx CoreTM were at 100% for
- 187 CYP2C9, CYP2C19 and SLCO1B1, and the diplotype-level call rates were at 100% for CYP2C9 and CYP2C19. The
- benchmark platform, Agena VeriDose® Core Panel, demonstrated call rates of >95.9% at the genotype-level and
- 189 >90.7% at the diplotype-level.
- 191 Most variants in CYP2D6, except for seven, achieved 100% call rates on Nala PGx CoreTM, while the corresponding
- call rates of the benchmark platforms were observed to be between 95.9 99.2% on Agena VeriDose® Core and
- 193 CYP2D6 CNV Panel, and 100% on TaqMan® DME Genotyping Assays. Out of the seven aforementioned variants,
- Nala PGx CoreTM demonstrated higher call rates than the benchmark for the genotyping of rs1065852. Intron 2 and
- 195 Exon 9 variants. For rs3892097, rs769258, rs5030865, and rs267608319, the accompanying benchmarks
- demonstrated higher call rates. At the diplotype-level, Nala PGx CoreTM demonstrated a CYP2D6 call rate of 95.9%
- as compared to the benchmark, which was observed to be at 90.7% (Table 3).

Precision

- A precision study was conducted to assess the consistency of Nala PGx CoreTM for samples tested under the same conditions (intra-precision) and under different conditions (inter-precision). Both study resulted in 100%
- concordance for all assays across replicates, demonstrating consistent genotyping results across a range of DNA
- 202 concentration, reagent lots and machine variations (Table 4). Precision of CYP2D6 CNV assay was reported as the
- average copy number obtained for Intron 2 and Exon 9 of three samples, and their CV calculated across the test
- 204 conditions (Table 5). The intra- CV ranged from 3-6% while inter- CV between 5-13%, demonstrating high
- precision of the assays across variables, where acceptable ranges were intra- CV below 10% and inter- CV below
- 206 15%³¹.

207208

215

Accuracy

- 209 Variant-level Concordance
- To assess the accuracy of the panel, 18 SNPs and 2 CYP2D6 Copy Number assays were genotyped on the panel,
- Nala PGx CoreTM, against benchmark methods as listed in Table 1. The 225 sample cohort consisted of DNA
- samples isolated from buccal swabs that had successfully produced genotype calls for all variants tested on Nala
- 213 PGx CoreTM and its benchmarks. The sample size per genotype displayed in Table 6 refers to the genotype calls
- 214 made by the benchmark.

216 11 variants (CYP2C9 rs1799853, rs1057910; CYP2C19 rs12248560; CYP2D6 rs5030655, rs3892097, rs35742686,

217 rs28371725, rs769258, rs5030656, rs59421388, rs267608319) were genotyped against Agena VeriDose® Core with

- a resulting concordance rate of 100% (N = 225 samples). Discordance was observed for CYP2C19 rs4244285 (n=7),
- 219 CYP2C19 rs4986893 (n=3), CYP2D6 rs1065852 (n=1), CYP2D6 rs16947 (n=7), CYP2D6 rs1135840 (n=5),
- 220 CYP2D6 rs5030865 (n=1) and SLCO1B1 rs4149056 (n=6), with a mismatch rate of 0.44% to 3.1% for the affected
- assays. Overall, Nala PGx CoreTM demonstrated >96% concordance to the benchmark, Agena VeriDose® Core, for
- the 16 variants across 225 samples (Table 6).
- Variants not present on Agena VeriDose® Core, CYP2D6 rs769258 and CYP2D6 rs267608319, were genotyped
- using TaqMan® DME Genotyping Assays. Nala PGx $Core^{TM}$ demonstrated 100% concordance (N = 225) to the
- benchmark for both SNPs.

218

223

227

232

235

243

248249

- For the CYP2D6 Intron 2 and Exon 9 Copy Number assays, concordance was observed to be at 99.6% and 98.7%
- respectively, against the Agena CYP2D6 CNV Panel. Discordant calls were observed in samples with an Intron 2
- copy number greater than 3 (n=1), and for samples with an Exon 9 copy number of one (n=1) and two (n=2). The
- sample size per copy number displayed in Table 7 refers to the copy number calls made by the benchmark.
- A summary of the concordance percentage as well as the distribution of genotypes of each variant are displayed in
- Table 6. Similarly, the distribution of *CYP2D6* Intron 2 and Exon 9 copy numbers are displayed in Table 7.
- 236 Diplotype-level Concordance
- Following successful genotyping at the variant level, we investigated the accuracy of Nala PGx CoreTM in assigning
- a diplotype call for CYP2C9, CYP2C19 and CYP2D6, with reference to the Agena VeriDose® Core and CYP2D6
- 239 CNV Panel. Table 8 displays the percentage concordance after the further exclusion of samples that demonstrated
- diplotype mismatches arising from technological differences, where technological differences refer to the varying
- allele coverage of each platform (Supplementary Table 7). These differences were derived from the variant lists of
- both Nala PGx CoreTM (Table 1) and its benchmark, the Agena VeriDose® Core and *CYP2D6* CNV Panel²⁶.
- Overall, a percentage agreement of 100% for CYP2C9 (n=221), 96.4% for CYPC219 (n=223) and 94.7% for
- 245 CYP2D6 (n=209) was observed between Nala PGx CoreTM and the benchmark. Discordance was observed at n=1
- for all diplotypes listed in Table 8 except for the following with more than one discordant calls: CYP2C19 *2/*2
- 247 (n=4), and CYP2D6 *4/*36 (n=2).

Frequencies By Ethnicity

- 250 For samples that were concordant on Nala PGx CoreTM and the benchmark platforms, we were able to observe the
- allele frequencies amongst the populations residing in Singapore and Indonesia (Table 9). From the combination of
- alleles present in individual's chromosome, we were able to observe both the diplotype and corresponding
- 253 phenotype frequencies amongst our study population (Table 10).

For *CYP2C9*, *3 allele was the most common amongst Chinese and Malay, and *2 allele amongst Caucasian, which is in line with PharmGKB's reported distribution for the East Asian and European populations respectively. Our study also reported *3 allele as the more common variant in Indian population than *2, as opposed to PharmGKB's frequency. These allele frequencies translated to *1/*3 as a common diplotype observed in Chinese, Malay and Indians, and *1/*2 in Caucasians.

For *CYP2C19*, we observed highest frequency of *CYP2C19*2* amongst Chinese, Malay and Indonesian which were categorized as East Asian populations. This resulted into high frequency of *1/*2 heterozygous depicted as a common diplotype amongst the population. The alleles *2 and *17 were observed as the common variants at equal proportions of 0.229 in Indians and 0.138 in Caucasians. *CYP2C19*3* was a common minor allele least observed amongst Indians and Caucasians, 0 and 0.017 respectively. As a result, *1/*2 and *1/*17 were common diplotypes observed in Indian and Caucasian populations, and *2/*17 only seen in Indians.

Common polymorphisms of *CYP2D6* in our population were seen in *10 and *36 alleles, at almost two-fold higher frequencies in Chinese, Malay and Indonesian than Indians. We noticed high frequencies of *36 in our East Asian population. Additionally, two functional copies of *36 allele were present in 1.4% of Chinese population who participated in our study (Figure 1). These alleles resulted in high frequency of *10/*36 as common diplotype amongst Chinese, Malay and Indonesian population. Our Indian population observed equal distribution of alleles *2, *10 and *36, although PharmGKB reported only *2 as the highest frequency in South Asians. The corresponding common diplotypes observed in Indians were of equal proportions in *1/*2, *1/*36 and *1/*10 ranging from 0.12 to 0.16. The alleles *2 and *4 were most common amongst Caucasians as reported by PharmGKB in Europeans, resulting in common diplotypes of *1/*2 and *1/*4 in the population.

For *SLCO1B1*, the frequencies of rs4149056 across all ethnicities were consistent with values reported in gnomAD, with the variant being most common amongst Caucasians (0.167) and least amongst Indians (0.040). The frequency amongst East Asians (0.125, gnomAD), as denoted by the Chinese and Indonesian ethnic groups in this study, ranged between 0.074 and 0.125 respectively.

Discussion

In this study, we evaluated the performance of Nala PGx CoreTM, a qPCR-based panel that evaluates 18 variants and 2 *CYP2D6* Copy Number markers across 4 pharmacogenes with established relevance across major ethnic groups in Singapore and Indonesia population. Nala PGx CoreTM comes coupled with a reporting software that supports variant detection, diplotype assignment, diplotype-to-phenotype translation and the generation of reports containing clinical recommendations for each phenotype. The panel demonstrated high genotype-level call rates of >97% for *CYP2D6*, and 100% for *CYP2C9*, *CYP2C19* AND *SLCO1B1*. Similarly, high diplotype-level call rates were observed at >95% for *CYP2D6*, and 100% for *CYP2C9* and *CYP2C19*. A precision of 100% was observed under the

same conditions (intra) and across different conditions (inter). In comparison to other established platforms serving as benchmarks during the study, Nala PGx CoreTM had \geq 96.9% concordance rate for all variant level assays, which consequently resulted in \geq 94.7% concordance at a diplotype level across *CYP2C9*, *CYP2C19* and *CYP2D6*.

Failures to produce a variant genotype call could be attributed to several reasons. Firstly, failures could potentially stem from the quality of gDNA, despite the DNA quality checks (QC) performed prior to accepting a sample for testing. Poor DNA quality could arise from multiple factors along the sample handling chain. Such factors include the contamination of the buccal fluid by interfering particles during sample collection, inconsistent conditions during sample transport and human error during sample purification. These may lead to the degradation of genomic DNA, poor homogenization of the sample in collection and/or extraction buffers, and the carryover of contaminants, thereby compromising sample integrity³². Further QC that involves specific quantification of double-stranded non-fragmented DNA and traces of other interfering materials like RNA, carryover carbohydrate, residual phenol, guanidine or other reagents could enhance the call rate³³. Regardless, the overall higher variant call rates on Nala PGx CoreTM panel demonstrate high tolerance of interfering substances, therefore alluding to the high robustness of the assay. Often, failures at variant genotyping subsequently contribute to failures at determining diplotype, since an incomplete variant panel cannot translate into a diplotype. Failures at diplotype calling could also arise from a combination of variants that do not map onto a distinct diplotype, per the reference database, potentially indicating a novel combination.

We further sought to evaluate the allele frequency distribution in the study cohort across the 5 major ethnic groups observed (Indonesian, Chinese, Malay, Indian and Caucasian). The data presented was limited strictly to the geographical boundaries of Singapore and Indonesia, which could account for the difference in allele frequencies observed in comparison to PharmGKB, which is representative of a more expansive and global cohort³⁴. Whilst dissimilar to database figures, our study demonstrated the distributions for the following to be concordant with previous studies^{7,35,36}, suggesting a niche in the PGx landscape of Singapore and Indonesia –

- 1. CYP2C9*3 allele as the more common variant within Indians than CYP2C9*2⁷
- 2. A SLCO1B1 rs4149056 frequency of 12.5% amongst Indonesians³⁵
- 3. High frequencies of the CYP2D6*10 amongst Indonesians³⁵
- 4. High frequencies of the CYP2D6*36 allele as seen in the Indonesian, Chinese and Malay ethnicities³⁶
- 5. Two functional copies of CYP2D6 within our Chinese population³⁶

Due to the lack of *CYP2D6* copy number references³⁵, it is our understanding that the frequency of *CYP2D6*36* in Indonesia may not be well-represented. Our study revealed that the prevalence of *CYP2D6*36* to be approximately seventeen times higher amongst Indonesians as compared to the corresponding East Asian allele frequency on PharmGKB³⁷. Furthermore, our study provides insight on the frequency of the *CYP2D6*10/*36* diplotype in the archipelago, which may help inform the adoption of population-specific PGx workflows in the region. Taken together, the data presents a case for extending tailored PGx testing across the 4 pharmacogenes studied, *CYP2C9*,

CYP2C19, CYP2D6 and SLCO1B1, in South East Asia.

Limitations

The single largest reason for the diplotype-level discordance observed between Nala PGx Core[™] and the Agena VeriDose® Core and *CYP2D6* CNV Panel appears to be a difference in the technological offerings and hence, allele coverage of each panel. From Supplementary Table 7, out of the 28 instances of discordance observed, 9 instances were attributed to this cause (32.1%). This included two alleles each in *CYP2C9*, *CYP2C19* and *CYP2D6*.

The variants *CYP2C9*12*, *CYP2C9*13*, *CYP2C19*4A*, *CYP2C19*6* and *CYP2D6*13* were covered by Agena VeriDose® Core but not by Nala PGx Core[™]. Due to lack of coverage for these alleles, the genotypes identified by Nala PGx Core[™] were inconsistent with the calls produced by Agena VeriDose® Core. It is important to note that Nala PGx Core[™] was curated specifically to include alleles that were relevant to Asian and European populations, with a Minor Allele Frequency (MAF) >1% based on PharmGKB database for East Asians, South Asians and Europeans³⁷. Similarly, *CYP2D6*35*, an allele present in 5.5% of Europeans and 1.2% of South Asians, was identified by Nala PGx Core[™] but not by Agena VeriDose® Core. The technological differences and subsequent inconsistencies in reporting suggest the need for further review from a product development standpoint.

For the highly polymorphic *CYP2D6* gene, Nala PGx CoreTM was designed to only cover the variant alleles listed in Table 1, that could lead to overestimation of *1 allele in our population. This means star alleles that may be present in the population were identified as normal genotype, which could result in overestimation of *1 allele in our population as compared to the PharmGKB's reported frequency (Supplementary Table 4).

The study also relied on self-reported ethnicity, which may have contributed to racial bias in summarizing the observed allele and diplotype frequencies per ethnic group. Future studies may consider screening the ethnicities of participants as well as their next-of-kin, up to two generations prior¹⁰, to improve classification accuracy.

Finally, the study cohort consisted of 246 individuals, with each ethnic group consisting of approximately 24 to 75 individuals for the frequency analysis. Larger scale studies may be conducted to ensure that the trends observed as part of this study may be generalized across the populations examined.

Future Work

Further investigation is required for the remaining samples that had discrepant genotypes across platforms. Nala PGx CoreTM was designed as a qPCR platform and genotyping was accompanied by Nala CDSTM that utilized quantitative thresholds. There could be cases of samples displaying borderline or ambiguous qPCR amplification curves and Ct-values, which could be misinterpreted by these thresholds. The benchmark platforms, Agena VeriDose® Core and *CYP2D6* CNV Panel and TaqMan® DME Genotyping Assays, were also analyzed by their accompanying software packages. Such ambiguous cases on either platform could lead to instances of discordance and sequencing of the region of interest may be required to ascertain the truth. For gene variants caused by SNPs and indels, the qPCR amplified product can be submitted for genome sequencing¹³. In the investigation of copy

- number variants, a two-step approach can be adopted³⁸. Firstly, CNV calls observed in this study may be checked
- against an alternative benchmark such as digital droplet PCR (ddPCR)³⁹. Secondly, where discordance in CNV
- 366 calling persists, methods such as XL-PCR can be adopted to identify the presence of CYP2D6/CYP2D7 hybrid
- states, with submitting samples for whole-genome sequencing³⁸ being an option. Investigation of copy number
- variants may require amplification of region spanning across the gene of interest.

369 **Conflict of Interest**

- A.S.K., M.T., J.P., J.T., C.M., G., J.S.H., and A.I. are employees of Nalagenetics Pte Ltd. A.I. and A.L. has financial
- 371 holdings in Nalagenetics Pte Ltd. Nalagenetics Pte Ltd and PT Nalagenetik Riset Indonesia are the license holders of
- Nala PGx CoreTM.

373 **Funding**

375376

All expenses for this study were funded by Nalagenetics Pte Ltd, Singapore, and PT Nalagenetik Riset Indonesia.

Data Availability Statement

- 377 The data that supports the findings of this study are available as supplementary materials. Any additional data is
- available from the corresponding author upon reasonable request.

379 References

- 380 1. Berm EJJ, Looff M de, Wilffert B, et al. Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature. Bruns H, ed. *PLoS One*. 2016;11(1):e0146262. doi:10.1371/journal.pone.0146262
- Chan SL, Ang X, Sani LL, et al. Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study. *Br J Clin Pharmacol*. 2016;82(6):1636-1646. doi:10.1111/bcp.13081
- 386 3. Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. *J Pharmacol Pharmacother*. 2013;4(SUPPL.1). doi:10.4103/0976-500X.120957
- 388 4. Zhu Y, Lopes GS, Bielinski SJ, et al. Impact of Pharmacogenomic Information on Values of Care and Quality of Life Associated with Codeine and Tramadol-Related Adverse Drug Events. *Mayo Clin Proc Innov Qual Outcomes*. 2021;5(1):35-45. doi:10.1016/j.mayocpiqo.2020.08.009
- Furge LL, Guengerich FP. Cytochrome P450 enzymes in drug metabolism and chemical toxicology: An introduction. *Biochem Mol Biol Educ*. 2006;34(2):66-74. doi:10.1002/bmb.2006.49403402066
- Malsagova KA, Butkova T V, Kopylov AT, et al. Pharmacogenetic Testing: A Tool for Personalized Drug Therapy Optimization. *Pharmaceutics*. 2020;12(12):1-23. doi:10.3390/pharmaceutics12121240
- Ling Goh L, Wei Lim C, Cheng Sim W, Xian Toh L, Pang Leong K. Analysis of Genetic Variation in CYP450 Genes for Clinical Implementation. 2017. doi:10.1371/journal.pone.0169233
- Kisor DF, Hoefer C, Decker BS. Pharmacogenomics and precision medicine. In: Clinical Pharmacy
 Education, Practice and Research: Clinical Pharmacy, Drug Information, Pharmacovigilance,
 Pharmacoeconomics and Clinical Research. Elsevier; 2018:437-451. doi:10.1016/B978-0-12-814276-9.00031-3
- 401
 402
 403
 Ooi BNS, Raechell, Ying AF, et al. Robust Performance of Potentially Functional SNPs in Machine Learning Models for the Prediction of Atorvastatin-Induced Myalgia. Front Pharmacol. 2021;12:605764. doi:10.3389/fphar.2021.605764
- 404 10. Brunham LR, Chan SL, Li R, et al. Pharmacogenomic diversity in Singaporean populations and Europeans.

- 405 *Pharmacogenomics J.* 2014;14(6):555-563. doi:10.1038/tpj.2014.22
- 406 11. Bachtiar M, Ooi BNS, Wang J, et al. Towards precision medicine: interrogating the human genome to identify drug pathways associated with potentially functional, population-differentiated polymorphisms.

 408 Pharmacogenomics J. 2019;19(6):516-527. doi:10.1038/s41397-019-0096-y
- 409 12. Perkel J. SNP genotyping: Six technologies that keyed a revolution. *Nat Methods*. 2008;5(5):447-453. doi:10.1038/nmeth0508-447
- 411 13. Yang W, Wu G, Broeckel U, et al. Comparison of genome sequencing and clinical genotyping for pharmacogenes. *Clin Pharmacol Ther*. 2016;100(4):380-388. doi:10.1002/cpt.411
- 413 14. S.A. Deepak, K.R. Kottapalli, R. Rakwal, et al. Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes. *Curr Genomics*. 2007;8(4):234-251. doi:10.2174/138920207781386960
- 415 15. Pratt VM, Zehnbauer B, Wilson JA, et al. Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: A GeT-RM and association for molecular pathology collaborative project. *J Mol Diagnostics*. 2010;12(6):835-846. doi:10.2353/jmoldx.2010.100090
- Pratt VM, Everts RE, Aggarwal P, et al. Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project. *J Mol Diagnostics*. 2016;18(1):109-123. doi:10.1016/j.jmoldx.2015.08.005
- 421 17. Syvänen AC. Accessing genetic variation: Genotyping single nucleotide polymorphisms. *Nat Rev Genet*. 422 2001;2(12):930-942. doi:10.1038/35103535
- 423 18. Suo W, Shi X, Xu S, Li X, Lin Y. Towards low cost, multiplex clinical genotyping: 4-fluorescent Kompetitive Allele-Specific PCR and its application on pharmacogenetics. Kalendar R, ed. *PLoS One*. 425 2020;15(3):e0230445. doi:10.1371/journal.pone.0230445
- 426 19. Shen GQ, Abdullah KG, Wang QK. The TaqMan method for SNP genotyping. *Methods Mol Biol*. 2009;578:293-306. doi:10.1007/978-1-60327-411-1_19
- Davis BH, DeFrank G, Limdi NA, Harada S. Validation of the Spartan RX CYP2C19 Genotyping Assay
 Utilizing Blood Samples. *Clin Transl Sci.* 2020;13(2):260-264. doi:10.1111/cts.12714
- 21. Zhou Y, Armstead AR, Coshatt GM, Limdi NA, Harada S. Comparison of two point-of-care cyp2c19 genotyping assays for genotype-guided antiplatelet therapy. *Ann Clin Lab Sci.* 2017;47(6):738-743.
- Bergmeijer TO, Vos GJ, Claassens DM, et al. Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy. *Pharmacogenomics*. 2018;19(7):621-628. doi:10.2217/pgs-2018-0013
- Chae H, Kim M, Koh Y-S, et al. Feasibility of a Microarray-Based Point-of-Care CYP2C19 Genotyping
 Test for Predicting Clopidogrel On-Treatment Platelet Reactivity. *Biomed Res Int.* 2013;2013:1-5.
 doi:10.1155/2013/154073
- 437 24. Lee CC, McMillin GA, Babic N, Melis R, Yeo K-TJ. Evaluation of a CYP2C19 genotype panel on the GenMark eSensor® platform and the comparison to the Autogenomics InfinitiTM and Luminex CYP2C19 panels. *Clin Chim Acta*. 2011;412(11-12):1133-1137. doi:10.1016/j.cca.2011.03.001
- Vanwong N, Ngamsamut N, Hongkaew Y, et al. Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels. *Drug Metab Pharmacokinet*. 2016;31(2):156-162. doi:10.1016/j.dmpk.2016.01.005
- Lois A, Everts RE, Nakorchevsky A, et al. The VeriDose Core Panel: Strong Performance When Analyzing
 Challenging Pharmacogenetic Samples. https://agenabio.com/wp-content/uploads/2020/06/Agena Conference-Poster-Veridose-Core-V3-G020.pdf. Accessed April 2, 2021.
- Gaedigk A, Turner A, Everts RE, et al. Characterization of Reference Materials for Genetic Testing of CYP2D6 Alleles. *J Mol Diagnostics*. 2019;21(6):1034-1052. doi:10.1016/j.jmoldx.2019.06.007
- Technologies L. TaqMan ® SNP Genotyping Assays TaqMan ® Predesigned SNP Genotyping Assays,

 TaqMan ® Custom SNP Genotyping Assays, and TaqMan ® Drug Metabolism Enzyme Genotyping Assays.;

 2014.
- 451 29. Population Genetics and the Hardy-Weinberg Principle.
- https://www.cs.cmu.edu/~genetics/units/instructions/instructions-PGE.pdf. Accessed May 2, 2021.
- 453 30. Allele frequency. https://www.nature.com/scitable/definition/allele-frequency-298/. Accessed May 2, 2021.
- 454 31. Calculating Inter- and Intra-Assay Coefficients of Variability. https://salimetrics.com/calculating-inter-and-intra-assay-coefficients-of-variability/. Accessed May 1, 2021.
- 456 32. Genomic DNA Preparation Troubleshooting. https://www.sigmaaldrich.com/ID/en/technical-
- documents/technical-article/genomics/dna-and-rna-purification/problems-during-genomic-dna-preparation.
 Accessed June 30, 2021.
- 459 33. Matlock B. Assessment of Nucleic Acid Purity. Tech Bull NanoDrop Spectrophotometers. 2015:1-2.
- 460 34. Huddart R, Fohner AE, Whirl □ Carrillo M, et al. Standardized Biogeographic Grouping System for

- Annotating Populations in Pharmacogenetic Research. *Clin Pharmacol Ther*. 2019;105(5):1256-1262. doi:10.1002/cpt.1322
- 463 35. Runcharoen C, Fukunaga K, Sensorn I, et al. Prevalence of pharmacogenomic variants in 100 pharmacogenes among Southeast Asian populations under the collaboration of the Southeast Asian Pharmacogenomics Research Network (SEAPharm). *Hum Genome Var.* 2021;8(1):7. doi:10.1038/s41439-021-00135-z
- 467 36. Chan W, Li MS, Sundaram SK, Tomlinson B, Cheung PY, Tzang CH. CYP2D6 allele frequencies, copy number variants, and tandems in the population of Hong Kong. *J Clin Lab Anal*. 2019;33(1). doi:10.1002/jcla.22634
- Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics Knowledge for Personalized Medicine. *Clin Pharmacol Ther*. 2012;92(4):414-417. doi:10.1038/clpt.2012.96

- 472 38. Pös O, Radvanszky J, Styk J, et al. Copy Number Variation: Methods and Clinical Applications. *Appl Sci*. 2021;11(2):819. doi:10.3390/app11020819
- 474 39. Gross AM, Ajay SS, Rajan V, et al. Copy-number variants in clinical genome sequencing: deployment and interpretation for rare and undiagnosed disease. *Genet Med.* 2019;21(5):1121-1130. doi:10.1038/s41436-018-0295-y

Tables

Table 1 Genes and variants evaluated

						Genotyping Methods Utilized		
Gene	Star Allele	Variant	Nucleotide Changes	Effect On Protein	Allele Clinical Function Status	Nala PGx Core TM	Agena VeriDose® Core and CYP2D6 CNV Panel	TaqMan® DME Genotyping Assays
CYP2C9	*2	rs1799853	3608C>T	R144C	Decreased	Bi-allelic Assay	VeriDose Core	
C112C)	*3	rs1057910	42614A>C	I359L	None	Bi-allelic Assay	VeriDose Core	
	*2	rs4244285	19154G>A	Splicing Defect	None	Bi-allelic Assay	VeriDose Core	
CYP2C19	*3	rs4986893	17948G>A	W212X	None	Bi-allelic Assay	VeriDose Core	
	*17	rs12248560	-806C>T	5' Region	Increased	Bi-allelic Assay	VeriDose Core	
	*2	rs1135840	4181G>C	S486T	Normal	Bi-allelic Assay	VeriDose Core	
	*2	rs16947	2851C>T	R296C	Normal	Bi-allelic Assay	VeriDose Core	
	*3	rs35742686	2550delA	Frameshift	None	Bi-allelic Assay	VeriDose Core	
	*4	rs3892097, rs1065852	1847G>A, 100C>T	Splicing Defect, P34S	None	Bi-allelic Assay	VeriDose Core	
	*5	N/A	N/A	Gene Deletion	None	CNV Assay (Intron 2)	CYP2D6 CNV	
	*6	rs5030655	1708delT	Frameshift	None	Bi-allelic Assay	VeriDose Core	
	*8	rs5030865	1759G>T	G169X	None	Tri-allelic Assay	VeriDose Core	
	*9	rs5030656	2616delAAG	K281del	Decreased	Bi-allelic Assay	VeriDose Core	
CYP2D6	*10	rs3892097, rs1065852	1847G>A, 100C>T	Splicing Defect, P34S	Decreased	Bi-allelic Assay	VeriDose Core	
	*14	rs5030865	1759G>A	G169R	Decreased	Tri-allelic Assay	VeriDose Core	
	*21	rs72549352	2580_2581ins C	Frameshift	None	Bi-allelic Assay	VeriDose Core	
	*29	rs59421388	3184G>A	V338M	Decreased	Bi-allelic Assay	VeriDose Core	
	*31	rs267608319	4043G>A	R440H	None	Bi-allelic Assay	NA	AH21B9N
	*35	rs769258	31G>A	V11M	Normal	Bi-allelic Assay	NA	C27102444_F0
	*36	N/A	Recombinatio n at Exon 9	CYP2D6-2D7 Hybrid	None	CNV Assay (Exon 9)	CYP2D6 CNV	
	*41	rs28371725	2989G>A	Splicing Defect	Decreased	Bi-allelic Assay	VeriDose Core	
SLC01B1	NA [†]	rs4149056	g.52422T>C	V174A	Decreased	Bi-allelic Assay	VeriDose Core	

[†]Nala PGx Core™ detects the variant, rs4149056, which is associated with decreased enzymatic activity and is present in three known *SLCO1B1* haplotypes namely, *SLCO1B1*5*, *SLCO1B1*15* and *SLCO1B1*17*.

Table 2 Observed genotype-level call rates per variant per gene per platform

485 486

		Variant Call Rate, % (n=246)						
Gene	Variant	Nala PGx Core™	Agena VeriDose® Core and CYP2D6 CNV Panel	TaqMan® DME Genotyping Assays				
CYP2C9	rs1799853	100.0	99.2	NA				
	rs1057910	100.0	99.6	NA				
CYP2C19	rs4244285	100.0	99.6	NA				
	rs4986893	100.0	99.6	NA				
	rs12248560	100.0	98.8	NA				
CYP2D6	rs1065852	98.4	95.9	NA				
	rs5030655	100.0	99.2	NA				
	rs3892097	98.8	99.2	NA				
	rs35742686	100.0	98.8	NA				
	rs16947	100.0	99.6	NA				
	rs28371725	100.0	99.2	NA				
	rs1135840	100.0	99.6	NA				
	rs769258	98.8	NA	100.0				
	rs5030865	97.2	99.2	NA				
	rs5030656	100.0	99.6	NA				
	rs59421388	100.0	99.2	NA				
	rs267608319	99.6	NA	100.0				
	CNV Assay (Intron 2)	99.6	99.2	NA				
	CNV Assay (Exon 9)	99.6	99.2	NA				
SLC01B1	rs4149056	100.0	99.2	NA				

 ${\bf Table~3~Observed~diplotype\text{-}level~call~rates~per~gene~per~platform}$

	Diplotype Call Rate, % (n=246)					
Gene	Nala PGx Core TM	Agena VeriDose® Core and CYP2D6 CNV Panel				
CYP2C9	100.0	97.2				
CYP2C19	100.0	98.8				
CYP2D6	95.9	90.7				

Table 4 Intra-precision and inter-precision concordance rates

	·	Concordance rate, %		
		Intra-precision	Inter-precision	
Gene	Variant	(47 tests in triplicate)	(120 tests across 4 variables)	
CVD2C0	rs1799853	100%	100%	
CYP2C9	rs1057910	100%	100%	
	rs4244285	100%	100%	
CYP2C19	rs4986893	100%	100%	
	rs12248560	100%	100%	
	rs1065852	100%	100%	
CYP2D6	rs5030655	100%	100%	
C1F2D0	rs3892097	100%	100%	
	rs35742686	100%	100%	

	rs16947	100%	100%
	rs28371725	100%	100%
	rs1135840	100%	100%
	rs769258	100%	100%
	rs5030865	100%	100%
	rs5030656	100%	100%
	rs59421388	100%	100%
	rs267608319	100%	100%
SLCO1B1	rs4149056	100%	100%

Table 5 Intra-precision and inter-precision for CYP2D6 Copy Number

Comple	Variant	Average Copy	Comple Sign n	Coefficient of Variation		
Sample	variant	Number	Sample Size, n	Intra-precision	Inter-precision	
221374	Intron 2	2	11	4%	6%	
	Exon 9	1		5%	5%	
222660	Intron 2	2	9	3%	5%	
	Exon 9	2		4%	6%	
222769	Intron 2	3	22	4%	10%	
	Exon 9	2		6%	13%	

Table 6 Genotype concordance for genes CYP2C9, CYP2C19, CYP2D6 and SLCO1B1

Gene	Variant	Genotype	Sample Size Per Genotype [†]	Concordance to Benchmark, % [‡]	Discordant Calls By Nala PGx Core ^{TMS}
CYP2C9	rs1799853	C/C	212	100.0	0
	N = 225	C/T	13		0
		T/T	0		0
	rs1057910	A/A	204	100.0	0
	N = 225	A/C	21		0
		C/C	0		0
CYP2C19	rs4244285	G/G	121	96.9	1
	N = 225	A/G	89		2
		A/A	15		4
	rs4986893	G/G	206	98.7	2
	N = 225	A/G	19		1
		A/A	0		0
	rs12248560	C/C	0	100.0	0
	N = 225	C/T	0		0
		T/T	0		0
CYP2D6	rs1065852	G/G	77	99.6	0
	N = 225	A/G	76		1
		A/A	72		0
	rs5030655	A/A	224	100.0	0
	N = 225	delA/A	1		0
		delA/delA	0		0
	rs3892097	C/C	205	100.0	0
	N = 225	C/T	16		0
		T/T	4		0
	rs35742686	T/T	225	100.0	0
	N = 225	delT/T	0		0
		delT/delT	0		0
	rs16947	G/G	145	96.9	2
	N = 225	A/G	64		4
		A/A	16		1
	rs28371725	C/C	204	100.0	0
	N = 225	C/T	19		0
		T/T	2		0
	rs1135840	C/C	33	97.8	1

	N = 225	C/G	68		1
		G/G	124		3
	rs769258	C/C	220	100.0	0
	N = 225	C/T	5		0
		T/T	0		0
	rs5030865	C/C	222	99.6	0
	N = 225	C/T	3		1
		T/T	0		0
	rs5030656	CTT/CTT	224	100.0	0
	N = 225	delCTT/CTT	1		0
		delCTT/delCTT	0		0
	rs59421388	C/C	224	100.0	0
	N = 225	C/T	1		0
		T/T	0		0
	rs267608319	C/C	225	100.0	0
	N = 225	C/T	0		0
		T/T	0		0
SLCO1B1	rs4149056	T/T	182	97.3	2
	N = 225	C/T	42		4
		C/C	1		0

[†] "Sample Size Per Genotype" reflects the counts of each genotype as produced by the benchmark, and not by Nala PGx Core™.

[‡] Refer to Table 1 for an outline of the benchmark methods used per variant.

[§] Discordant calls refer to instances in which Nala PGx Core™ did not produce a genotype call concordant with the benchmark.

495 496

497

Table 7 Genotype concordance for CYP2D6 Intron 2 And Exon 9 Copy Number Variations

Gene	Variant	Copy Number	Sample Size Per Copy Number [†]	Concordance to Benchmark, % [‡]	Discordant Calls By Nala PGx Core™§
CYP2D6	Intron 2	0	0	99.6	0
	N = 224	1	12		0
		2	130		0
		>=3	82		1
	Exon 9	0	0	98.7	0
	N = 224	1	24		1
		2	193		2
		>=3	7		0

[†] "Sample Size Per Copy Number" reflects the counts of each copy number call as produced by the benchmark, and not by Nala PGx CoreTM

[‡] Refer to Table 1 for an outline of the benchmark methods used per variant.

[§] Discordant calls refer to instances in which Nala PGx CoreTM did not produce a copy number call concordant with the benchmark.

Table 8 Diplotype concordance for CYP2C9, CYP2C19 and CYP2D6 between Nala PGx CoreTM, and Agena VeriDose® Core and CYP2D6 CNV Panel

		Discordant Diplotypes						
Genes	Concordance, % [†]	Agena VeriDose® Core and CYP2D6 CNV Panel	Nala PGx Core TM	Instances				
CYP2C9	100% (n = 221)	NA	NA	NA				
CYP2C19	96.4% (n = 223)	*1/*1	*1/*3	1				
		*1/*2	*1/*1	1				
		*1/*2	*1/*3	1				
		*1/*3	*2/*2	1				
		*2/*2	*1/*1	2				
		*2/*2	*1/*2	2				
CYP2D6	94.7% (n = 209)	*1/*1	*2/*2	1				
		*1/*10	*1/*10, CN >=3	1				
		*1/*41	*39/*41	1				
		*2/*2	*1/*1	1				

*2/*10	*1/*10	1
*2/*36, CN >=3	*2/*10, CN >=3	1
*4/*36	*4/*10	2
*10/*36	*2/*36	1
*13 *1/*10	*1/*10, CN >=3	1
*13 *1/*41, CN = 1	*1/*41	1

The concordance presented in this table excludes samples that have mismatches in diplotype calls arising from technological differences between platforms. Please refer to Supplementary Table 7 for a detailed breakdown of all diplotypes detected.

Table 9 Observed allele frequencies by ethnicity

498 499

500 501

Table	Josefved affen	l	os by cuii		anencies (1	Per This Study)	Allele F	requencies (F	PharmGKR)
Gene	Allele or Variant	Indonesian	Chinese	Malay	Indian	Caucasian	Overall	East Asian	Central/ South Asian	European
CYP2C9	*2	0.000	0.000	0.000	0.060	0.172	0.032	0.002	0.114	0.127
(n = 206)	*3	0.000	0.040	0.039	0.100	0.069	0.044	0.038	0.110	0.076
	*2	0.297	0.274	0.289	0.229	0.138	0.256	0.284	0.270	0.147
CYP2C19 (n = 201)	*3	0.041	0.055	0.066	0.000	0.017	0.042	0.072	0.016	0.002
(H = 201)	*17	0.054	0.007	0.039	0.229	0.138	0.067	0.021	0.171	0.216
	*2	0.088	0.118	0.167	0.140	0.196	0.136	0.121	0.295	0.277
	*4	0.000	0.035	0.069	0.020	0.161	0.051	0.005	0.091	0.185
	*5	0.029	0.028	0.028	0.080	0.000	0.031	0.049	0.046	0.030
	*6	0.000	0.000	0.000	0.000	0.018	0.003	0.000	0.000	0.011
CYP2D6	*9	0.000	0.000	0.000	0.000	0.018	0.003	0.002	0.003	0.028
(n = 195)	*10	0.338	0.299	0.222	0.160	0.143	0.251	0.436	0.087	0.016
	*14	0.000	0.014	0.000	0.000	0.000	0.005	0.003	ND	0.000
	*29	0.000	0.000	0.000	0.000	0.018	0.003	0.000	0.003	0.001
	*36	0.206	0.250	0.181	0.160	0.054	0.190	0.012	0.000	0.000
	*41	0.044	0.056	0.028	0.040	0.071	0.049	0.023	0.123	0.092
SLCO1B1 (n = 203)	rs4149056 [†]	0.125	0.074	0.026	0.040	0.167	0.084	0.125‡	0.050‡	0.159‡

[&]quot;ND" refers to instances in which no data is available for the given allele on PharmGKB.

Table 10 Observed diplotype frequencies by ethnicity

	Diplotype	Phenotype [‡]	Diplotype Frequencies (Per This Study) [†]											
Gene			Indonesian		Chinese		Malay		Indian		Caucasian		Overall	
			Obs	Freq	Obs	Freq	Obs	Freq	Obs	Freq	Obs	Freq	Obs	Freq
CYP2C9	*1/*1	NM	39	1.000	69	0.920	35	0.921	17	0.680	16	0.552	176	0.854
	*1/*2	IM	0	0.000	0	0.000	0	0.000	3	0.120	9	0.310	12	0.058
	*1/*3	IM	0	0.000	6	0.080	3	0.079	5	0.200	3	0.103	17	0.083
	*2/*3	PM	0	0.000	0	0.000	0	0.000	0	0.000	1	0.034	1	0.005
CYP2C19	*1/*1	NM	10	0.270	31	0.425	14	0.368	8	0.333	14	0.483	77	0.383
	*1/*2	IM	19	0.514	28	0.384	14	0.368	5	0.208	7	0.241	73	0.363
	*1/*3	IM	3	0.081	6	0.082	3	0.079	0	0.000	1	0.034	13	0.065
	*1/*17	RM	3	0.081	1	0.014	1	0.026	5	0.208	5	0.172	15	0.075
	*2/*2	PM	1	0.027	5	0.068	3	0.079	1	0.042	0	0.000	10	0.050
	*2/*3	PM	0	0.000	2	0.027	2	0.053	0	0.000	0	0.000	4	0.020
	*2/*17	IM	1	0.027	0	0.000	0	0.000	4	0.167	1	0.034	6	0.030
	*17/*17	UM	0	0.000	0	0.000	1	0.026	1	0.042	1	0.034	3	0.015
CYP2D6	*1/*1	NM	6	0.176	7	0.097	5	0.139	4	0.160	2	0.071	24	0.123
	*1/*2	NM	0	0.000	2	0.028	2	0.056	3	0.120	3	0.107	10	0.051
	*1/*2, CN >=3	UM	0	0.000	0	0.000	0	0.000	1	0.040	1	0.036	2	0.010
	*1/*4	IM	0	0.000	2	0.028	1	0.028	0	0.000	4	0.143	7	0.036
	*1/*5	IM	0	0.000	2	0.028	1	0.028	1	0.040	0	0.000	4	0.021

[†]rs4149056 refers to the reduced function variant of *SLCO1B1* that is present in *SLCO1B1*5*, *SLCO1B1*15* and *SLCO1B1*17*. [‡]Allele frequency values for rs4149056 have been obtained from gnomAD.


*1/*6	IM	0	0.000	0	0.000	0	0.000	0	0.000	1	0.036	1	0.005
*1/*10	NM	4	0.118	3	0.042	2	0.056	2	0.080	2	0.071	13	0.067
*1/*14	NM	0	0.000	1	0.014	0	0.000	0	0.000	0	0.000	1	0.005
*1/*29	NM	0	0.000	0	0.000	0	0.000	0	0.000	1	0.036	1	0.005
*1/*36	IM	3	0.088	3	0.042	5	0.139	4	0.160	0	0.000	15	0.077
*1/*41	NM	1	0.029	2	0.028	1	0.028	0	0.000	2	0.071	6	0.031
*1/*41, CN >=3	UM	0	0.000	0	0.000	0	0.000	1	0.040	0	0.000	1	0.005
*2/*2	NM	0	0.000	1	0.014	1	0.028	1	0.040	1	0.036	4	0.021
*2/*4	IM	0	0.000	0	0.000	1	0.028	0	0.000	2	0.071	3	0.015
*2/*5	IM	0	0.000	0	0.000	1	0.028	1	0.040	0	0.000	2	0.010
*2/*10	NM	4	0.118	4	0.056	4	0.111	0	0.000	1	0.036	13	0.067
*2/*14	NM	0	0.000	1	0.014	0	0.000	0	0.000	0	0.000	1	0.005
*2/*36	IM	2	0.059	4	0.056	2	0.056	0	0.000	1	0.036	9	0.046
*2/*41	NM	0	0.000	4	0.056	0	0.000	0	0.000	1	0.036	5	0.026
*4/*4	PM	0	0.000	1	0.014	1	0.028	0	0.000	1	0.036	3	0.015
*4/*5	PM	0	0.000	0	0.000	0	0.000	1	0.040	0	0.000	1	0.005
*4/*9	IM	0	0.000	0	0.000	0	0.000	0	0.000	1	0.036	1	0.005
*4/*10	IM	0	0.000	1	0.014	1	0.028	0	0.000	0	0.000	2	0.010
*5/*10	IM	0	0.000	2	0.028	0	0.000	1	0.040	0	0.000	3	0.015
*5/*41	IM	2	0.059	0	0.000	0	0.000	0	0.000	0	0.000	2	0.010
*10/*10	IM	3	0.088	1	0.014	2	0.056	0	0.000	2	0.071	8	0.041
*10/*10, CN >=3	IM	0	0.000	1	0.014	0	0.000	0	0.000	0	0.000	1	0.005
*10/*36	IM	9	0.265	28	0.389	5	0.139	4	0.160	1	0.036	47	0.241
*10/*41	IM	0	0.000	1	0.014	0	0.000	1	0.040	0	0.000	2	0.010
*36/*41	IM	0	0.000	1	0.014	1	0.028	0	0.000	1	0.036	3	0.015

Figures and Legends

502

503 504

Figure 1. CYP2D6*36 Frequency By Ethnicity. Distribution of individuals carrying one or two copies of the CYP2D6*36 allele among the study cohort (n=205), grouped per ethnicity.



^{*&}quot;Obs" and "Freq" are abbreviations for "Observations" and "Frequency" respectively.

*"NM, "IM, "PM" and "UM" are abbreviations for "Normal Metabolizer", "Intermediate Metabolizer", "Poor Metabolizer" and "Ultrarapid Metabolizer" respectively.

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

Supplementary Tables And Figure Legends Supplementary Table 1. Observed Genotype-Level Call Rates Per Variant Per Gene Per Platform, With Counts Of Successful And No Calls Supplementary Table 2. Observed Diplotype-Level Call Rates Per Gene Per Platform, With Counts Of Successful And No Calls Supplementary Table 3. Precision Analysis Of Nala PGx Core[™] **Supplementary Table 4.** Observed allele frequencies by ethnicity Supplementary Table 5. CYP2D6 Intron 2 And Exon 9 Observations And Frequencies By Ethnicity Supplementary Table 6. CYP2D6*36 Observations And Frequencies By Ethnicity Supplementary Table 7. Diplotype Calls Observed Across All Samples Tested On Agena Veridose® Core And CYP2D6 CNV Panel And Nala PGx Core™ Supplementary Table 8. Raw And Reported Diplotype Concordance Values For Samples Tested On Agena Veridose® Core And CYP2D6 CNV Panel And Nala PGx Core™ **Supplementary Tables 9.1 to 9.18.** Raw genotype calls for rs1799853, rs1057910, rs4244285, rs4986893, rs12248560, rs1065852, rs5030655, rs3892097, rs35742686, rs16947, rs28371725, rs1135840, rs769258, rs5030865, rs5030656, rs59421388 and rs267608319, on Nala PGx Core™ and the corresponding benchmark methods, Agena VeriDose® Core and CYP2D6 CNV Panel or TaqMan® DME Genotyping Assays Supplementary Table 9.19. Raw variant calls for CYP2D6 Intron 2 and Exon 9 on Agena VeriDose® Core and CYP2D6 CNV Panel and Nala PGx CoreTM Supplementary Figure 1. Observed CYP2D6 Functional Copy Number Frequencies By Ethnicity. Distribution of individuals carrying one, two or three or more copies of the CYP2D6 functional gene among the study cohort (n=205), grouped per ethnicity.